LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・ADMA Biologics Inc

ADMA Biologics Inc

Chiusa

SettoreSettore sanitario

8.15 -3.44

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.08

Massimo

8.19

Metriche Chiave
By Trading Economics
Entrata	13M 49M
Vendite	4.9M 139M
P/E Media del settore	17.475 49.8
EPS	0.216
Margine di Profitto	35.483
Dipendenti	640
EBITDA	14M 65M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+189.72% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.5B 2.4B
Apertura precedente	11.59
Chiusura precedente	8.15

Notizie sul Sentiment di mercato

By Acuity

75%

25%

324 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

N/A / 23.5406 Supporto e resistenza

ADMA Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 mag 2026, 06:05 UTC

Utili

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mag 2026, 15:36 UTC

Discorsi di Mercato

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

Utili

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mag 2026, 15:05 UTC

Discorsi di Mercato

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mag 2026, 14:42 UTC

Discorsi di Mercato

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

Confronto tra pari

Modifica del prezzo

ADMA Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

189.72% in crescita

Previsioni per 12 mesi

Media 23.67 USD 189.72%

Alto 30 USD

Basso 20 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ADMA Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a ADMA Biologics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 23.5406Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bullish event.

Sentiment

By Acuity

324 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.